01—Abstract
Summary
Summary of the 8-K filed May 29, 2024. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc filed this Form 8-K under Item 8.01 (Other Events) to disclose that Johnson and Johnson announced positive results from the pivotal Phase 3 MDD3001 clinical trial of seltorexant.
Seltorexant is described as a potential first-in-class selective antagonist of the human orexin-2 receptor, being studied as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms. According to the filing, the study met all primary and secondary endpoints and was safe and well-tolerated. The filing notes that there are currently no approved therapies to treat MDD with insomnia symptoms, and that the findings will be presented at this year's American Society of Clinical Psychopharmacology Annual Meeting.
For Royalty Pharma, the filing states the company is entitled to a mid-single digit royalty on worldwide net sales of seltorexant. The filing also cites Johnson and Johnson's December 2023 Enterprise Business Review, in which the company stated that seltorexant has the potential for non-risk adjusted peak sales of between $1 billiona and $5 billion.
The filing is a disclosure of a third-party clinical milestone rather than a financial result for Royalty Pharma, and it includes no quantified financial impact on the company's own results. Investors should view it as a pipeline-related development affecting a royalty asset whose future value depends on commercialization and regulatory outcomes, which the filing does not address.
02—Key points
Key Highlights
- Johnson and Johnson announced positive Phase 3 MDD3001 results for seltorexant on May 29, 2024, with all primary and secondary endpoints met.
- Seltorexant is described as a potential first-in-class selective orexin-2 receptor antagonist for major depressive disorder with insomnia symptoms.
- The study population was moderately-to-severely depressed despite ongoing SSRI/SNRI treatment and had significant sleep disturbance.
- The filing states there are currently no approved therapies to treat MDD with insomnia symptoms.
- Royalty Pharma is entitled to a mid-single digit royalty on worldwide net sales of seltorexant.
- Johnson and Johnson's December 2023 Enterprise Business Review cited non-risk adjusted peak sales potential of between $1 billion and $5 billion for seltorexant.
- Findings will be presented at this year's American Society of Clinical Psychopharmacology Annual Meeting.
03—Questions
Frequently Asked Questions
What did the Phase 3 MDD3001 trial of seltorexant show?
According to the filing, seltorexant met all primary and secondary endpoints in the Phase 3 MDD3001 study and was safe and well-tolerated in patients with moderately-to-severely depressed MDD with insomnia symptoms despite ongoing SSRI/SNRI treatment.
How does Royalty Pharma benefit from seltorexant?
The filing states Royalty Pharma is entitled to a mid-single digit royalty on worldwide net sales of seltorexant, so its economics depend on the drug's future sales.
What sales potential has been projected for seltorexant?
Johnson and Johnson stated at its December 2023 Enterprise Business Review that seltorexant has the potential for non-risk adjusted peak sales of between $1 billion and $5 billion.
Why is this development significant for the treatment market?
The filing notes that there are currently no approved therapies to treat MDD with insomnia symptoms, and describes seltorexant as a potential first-in-class selective orexin-2 receptor antagonist.
Where and when will the detailed results be presented?
The filing states the findings will be presented at this year's American Society of Clinical Psychopharmacology Annual Meeting.
04—Continue